Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial

• Published in: European journal of heart failure Vol. 17; no. 7; pp. 735 - 742
• Main Authors: Zannad, Faiez, Greenberg, Barry, Cleland, John G.F., Gheorghiade, Mihai, van Veldhuisen, Dirk J., Mehra, Mandeep R., Anker, Stefan D., Byra, William M., Fu, Min, Mills, Roger M.
• Format: Journal Article
• Language: English
• Published: Oxford, UK John Wiley & Sons, Ltd 01.07.2015; European Society of Cardiology (Wiley)
• Subjects: Administration, Oral; antithrombotic; Cardiology and cardiovascular system; Coronary Artery Disease; Coronary Artery Disease - drug therapy; Coronary Artery Disease - mortality; Double-Blind Method; Factor Xa Inhibitors; Factor Xa Inhibitors - therapeutic use; Heart Failure; Heart Failure - drug therapy; Heart Failure - mortality; Human health and pathology; Humans; Life Sciences; Myocardial Infarction; Myocardial Infarction - prevention & control; Original; Prospective Studies; Research Design; Risk Factors; Rivaroxaban; Rivaroxaban - therapeutic use; Stroke; Stroke - prevention & control; Study Design; Survival Rate; thrombin; coronary artery disease; heart failure; rivaroxaban; thrombin; antithrombotic

Aims Thrombin is a critical element of crosstalk between pathways contributing to worsening of established heart failure (HF). The aim of this study is to explore the efficacy and safety of rivaroxaban 2.5 mg bid compared with placebo (with standard care) after an exacerbation of HF in patients with...